CE088

CE088 is a preclinical cancer vaccine candidate being developed by Cello Therapeutics. It is built upon the company's proprietary Cellular Nanoparticle (CNP) platform, which utilizes nanoparticles (typically with a polymeric core like PLGA) encapsulated within natural cell membranes derived from sources such as red blood cells or tumor cells. This biomimetic approach is designed to improve the delivery of antigens to the immune system, enhance biocompatibility, and reduce the clearance of the therapeutic by the mononuclear phagocyte system. While the specific target antigens for CE088 have not been publicly disclosed, the program is part of a broader pipeline aimed at leveraging nanotechnology for immuno-oncology and the treatment of solid tumors.